HYPERIUM ( DrugBank: HYPERIUM )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 1 |
8. Huntington disease
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-018119-14-GB (EUCTR) | 23/07/2010 | 18/06/2010 | Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study | Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study | Huntington's Disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Hyperium Product Name: Rilmenidine INN or Proposed INN: Rilmenidine | Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | NULL | Not Recruiting | Female: yes Male: yes | 16 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom |